Cost-effectiveness of pembrolizumab plus axitinib vs nivolumab plus ipilimumab as first-line treatment of advanced renal cell carcinoma in the US

TR Watson, X Gao, KL Reynolds… - JAMA Network Open, 2020 - jamanetwork.com
Importance Checkpoint inhibitor combination therapy represents a major advance in the first-
line treatment of advanced renal cell carcinoma. Pembrolizumab-axitinib and nivolumab …
被引用次数：29 相关文章
[PDF] academia.edu

[PDF][PDF] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

TR Watson, X Gao, KL Reynolds, CY Kong - academia.edu
IMPORTANCE Checkpoint inhibitor combination therapy represents a major advance in the
first-line treatment of advanced renal cell carcinoma. Pembrolizumab-axitinib and nivolumab …

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.

TR Watson, X Gao, KL Reynolds… - JAMA Network …, 2020 - search.ebscohost.com
This economic evaluation compares the cost-effectiveness of pembrolizumab-axitinib vs
nivolumab-ipilimumab for treatment of advanced renal cell carcinoma (ARCC) in the US …

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.

TR Watson, X Gao, KL Reynolds, CY Kong - JAMA Network Open, 2020 - europepmc.org
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line
Treatment of Advanced Renal Cell Carcinoma in the US. - Abstract - Europe PMC Sign in …
[HTML] nih.gov

[HTML][HTML] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

TR Watson, X Gao, KL Reynolds, CY Kong - JAMA Network Open, 2020 - ncbi.nlm.nih.gov
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line
Treatment of Advanced Renal Cell Carcinoma in the US - PMC Back to Top Skip to main …

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US

TR Watson, X Gao, KL Reynolds… - JAMA network …, 2020 - pubmed.ncbi.nlm.nih.gov
Importance Checkpoint inhibitor combination therapy represents a major advance in the first-
line treatment of advanced renal cell carcinoma. Pembrolizumab-axitinib and nivolumab …

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.

TR Watson, X Gao, KL Reynolds, CY Kong - JAMA Network Open, 2020 - europepmc.org
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line
Treatment of Advanced Renal Cell Carcinoma in the US. - Abstract - Europe PMC Sign in …